文献速递肿瘤 PET/CT核素与放射性配体治疗

局灶性免疫治疗相关胰腺炎在FDG PET/CT上模拟转移瘤

Focal Immunotherapy-Induced Pancreatitis Mimicking Metastasis on FDG PET/CT.
PubMed 文献 · Clin Nucl Med · 2019-01-01

一例46岁转移性肺腺癌男性患者接受帕博利珠单抗治疗3周期后行FDG PET/CT,发现胰尾局灶性增大伴SUVmax 7,经皮质激素治疗并停用帕博利珠单抗后影像学消退,诊断为局灶性免疫治疗相关胰腺炎。免疫检查点抑制剂可产生FDG高摄取的独特不良反应谱,可能模拟转移性疾病。

要点

  • 免疫检查点抑制剂可致局灶性胰腺炎,FDG PET/CT上可模拟转移。
  • 帕博利珠单抗治疗3周期后胰尾局灶性增大伴SUVmax 7。
  • 皮质激素治疗并停药后影像学消退,支持免疫相关不良反应诊断。

核心结论

  • 免疫检查点抑制剂治疗后可出现FDG高摄取的局灶性胰腺炎,影像表现可模拟转移瘤。

研究设计与样本

  • 单例病例报告:46岁转移性肺腺癌男性,帕博利珠单抗治疗3周期后行FDG PET/CT。

主要发现

  • FDG PET/CT显示胰尾局灶性增大,SUVmax为7。
  • 经皮质激素治疗并停用帕博利珠单抗后,影像学消退,诊断为局灶性免疫治疗相关胰腺炎。

关键数值与推荐

  • 胰尾局灶性增大伴SUVmax 7,经皮质激素治疗并停用帕博利珠单抗后影像学消退。

临床怎么用

  • 解读FDG PET/CT时需认识免疫检查点抑制剂相关FDG高摄取不良反应的影像特征,以避免误判为转移并支持及时决策治疗。

局限性

  • 单例病例报告,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 46-year-old man with metastatic lung adenocarcinoma was treated with pembrolizumab. FDG PET/CT was performed after 3 cycles of treatment and revealed a focal region of pancreatic tail enlargement with an SUVmax value of 7. Following treatment with corticosteroids and discontinuation of pembrolizumab, radiological resolution was observed, and a diagnosis of focal immunotherapy-induced pancreatitis was made. A unique spectrum of FDG-avid adverse events can develop in patients treated with immune-checkpoint inhibitors that may mimic metastatic disease. Knowledge of the radiologic features of these potential imaging pitfalls is crucial among those interpreting FDG PET/CT to allow prompt and decisive treatment.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Das JP, Halpenny D, Do RK, et al. Focal Immunotherapy-Induced Pancreatitis Mimicking Metastasis on FDG PET/CT. Clin Nucl Med. 2019. PMID: 31283599. doi:10.1097/RLU.0000000000002692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。